<DOC>
	<DOCNO>NCT01139788</DOCNO>
	<brief_summary>Study CXBA multicenter nonrandomized , dose escalation , open-label , Phase 1 study intravenous LY2624587 patient advance metastatic cancer treatment high priority exists .</brief_summary>
	<brief_title>A Study LY2624587 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Present histological cytological evidence diagnosis cancer ( solid tumor , lymphoma , chronic lymphocytic leukemia ) advance and/or metastatic . The patient must , judgement investigator , appropriate candidate experimental therapy available standard therapy use . Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) , Revised International Working Group Lymphoma Response Criteria , National Cancer Institute Working Group Guidelines Chronic Lymphocytic Leukemia . Have adequate organ function . Have performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) scale . Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug . Females child bear potential must negative serum pregnancy test less equal 7 day prior first dose study drug . Have discontinue chemotherapy cancerrelated hormonal therapy commerciallyavailable agent least 21 day ( 6 week mitomycinC nitrosoureas ) radiotherapy least 14 day prior study enrollment recover acute effect therapy ( less equal National Cancer Institute 's Common Terminology Criteria Adverse Events ( CTCAE v 4.02 ; Grade 1 ) . Hormone refractory prostate cancer patient receive gonadotropin release hormone ( GnRH ) agonist therapy breast cancer patient antiestrogen therapy ( example , aromatase inhibitor ) prior entrance study may treatment continue enrol Study CXBA . Have estimate life expectancy great equal 12 week . Have receive treatment investigational drug , receive regulatory approval indication , within 28 day study treatment LY2624587 . Have medical condition , opinion investigator , would preclude participation study . Have symptomatic central nervous system malignancy metastasis . Patients treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , currently receive corticosteroid and/or anticonvulsant . Screening asymptomatic patient without history CNS metastases require . Have history major organ transplant . Have current acute leukemia . Have active human immunodeficiency virus , hepatitis B surface antigen , hepatitis C antibody . Have QTc great 470 msec ( female ) great than450 msec ( male ) , history congenital long QT syndrome conduction abnormality . Have autologous allogenic bone marrow transplant . Previously treat CXCR4 antagonist , significant allergy biologic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Cancer</keyword>
</DOC>